Member Info for Wigwammer

Thanks popeye. Very kind… Posters like juxtaposition are - of course - entitled to their opinion. But he hasn’t addressed the point I made, and it’s pretty obvious why… IMO DYOR GLA

Nolupus, I think it was closer to £800k, but never mind. The point is the “spade” is vastly smaller than the one you originally suggested. IMO DYOR GLA

Nolupus - I have no more desire to have the last word than anyone else. But your “decided to invest £2m” point clearly lacks important context. The actual net investment ended up being materially less than £1m. You are famous for your half truths, but this is slightly less than even that… IMO DYOR GLA

Perhaps worth mentioning also, Tim’s decision to raise £10m for very marginal dilution in early 2018 (around 10x what they lost on incanthera). A smart move at a time when he couldn’t have known the outcome of the ph3 trial… I have no particular reason to defend or attack Tim, I’m sure he has done some things well and some not so well. But he is just one part of the investment equation. In the meantime, the science and patent development is building value. IMO DYOR GLA

I suspect it was materially less than even £1m, nolupus. But certainly nothing like the £2m you originally stated. DYOR GLA

Probably worth mentioning (but it wasn’t) that £1.5m of the £2m was recovered when they sold incanthera shares in June 2024. Good luck IMMers

Hmm. So clairvoyant that despite the shares moving between 1p and 18p over the last 2 years, they haven’t made a single profitable call … 😂

Now you’re being silly and childish, juxta… The new facility didn’t start today, did it? And if we pro rata the facility from May, Lanstead will have sold nearly 10m shares. Yet the price has held up, suggesting someone is buying material amounts in the background. So to repeat - Laura has a point, there appears to be a material buyer or buyers out there. IMO GLA DYOR

Were the bears not repeatedly talking about a block seller called Lanstead, who were supposed to dump shares as soon as the new facility started in May? Yet the shares have held steady, if not positively consolidated… So Laura has a good point - there is evidently a sizeable buyer(s) on the other side, mopping up shares and keeping the price buoyant. Unless of course, the bears now think Lanstead are not really selling after all. IMO DYOR GLA

Is someone forgetting that the auditor would not have passed the accounts in May, unless explicit proof was given that the company has cash for at least the next 12 months?... Come on England 🏴󠁧󠁢󠁥󠁮󠁧󠁿🏴󠁧󠁢󠁥󠁮󠁧󠁿🏴󠁧󠁢󠁥󠁮󠁧󠁿

“ A respected poster, would not write that..” says nolupus… Immupharma started the year with £1.4m cash. If they add £3.3m through the new facility at the current price, it gives them a total of £4.7m. Given the cash burn is around £2.3m pa, this would provide sufficient cash to get them to early 2028, or conservatively mid 2027, as I stated… But “whatever” 😂

It appears juxtaposition’s warning has prompted a flurry of buying. Now there’s a respected poster 😂

Well said, valid point. But a reassuring indication of the fomo when a sceptic is scouring the annual report on a Wednesday afternoon. Plenty of buyers waiting in the wings… with respect Laura, the 2028 cash projection relies on the shares being materially above where we are now, but mid 2027 looks about right at the current price. IMO DYOR GLA

Gosh juxtaposition does try very hard doesn’t he? But he evidently has no interest in helping anyone here. The statement quoted is a standard belt and braces requirement for any development stage company. Immupharma is funded well into next year, giving them a meaningful cash runway to get a deal done. IMO DYOR and good luck all IMMers!

Two points.. 1) great for lupus sufferers that effective help is at hand… 2) a succesful p140 would be cheaper and easier to administer, so would likely steal the show from CAR-T… of course, they have to prove p140 works in a trial first, but what’s new? … IMO DYOR GLA

Car-t costs hundreds of thousands to manufacture and administer. By contrast, p140 is a low cost synthetic peptide delivered by injection. Very different economics. IMO DYOR GLA

Yes the patent application could add 20 years exclusivity, and management have a great story to tell about the fundamentals. Little wonder people fear missing out. IMO DYOR GLA

In the meantime, immupharma shares reached 18p+ last year while lanstead were selling (contrary to what was stated earlier). And lanstead retain material long term exposure through their option holding which they appear in no hurry to divest (contrary to what was suggested earlier). IMO DYOR GLA

Juxtaposition is incorrect again. The last Lanstead agreement completed in November 2025 and this did not stop the shares rallying to 18p+ in the prior months. Lanstead continue to have long term equity exposure through their option holdings (c70m) which - despite repeated warnings from the sceptics - they have not monetised even at the higher levels. IMO DYOR GLA

I don’t think msuk’s analysis has helped anybody make money here over the last 18 months. If you had used 50/200 day moving averages in Jan and Sept 2025 then you would have missed the key positive days, and your return would be cut to the bone. The benefits of TA are an illusion - which is why there is so little empirical evidence supporting them… Fundamentals, valuation, taking sensible profit, patience - much more prevalent among succesful investors. IMO DYOR GLA